Vigilare Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Vigilare Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-470	Closed	-$297K	–	163
2021 Q4	$297K	Hold	470	–	–	0.18%	141
2021 Q3	$284K	Sell	470 -45	-9%	-$27.9K	0.18%	149
2021 Q2	$288K	Sell	515 -140	-21%	-$70.9K	0.17%	150
2021 Q1	$310K	Buy	+655	New	+$319K	0.22%	128
2020 Q4	–	Sell	-415	Closed	-$232K	–	158
2020 Q3	$232K	Buy	+415	New	+$252K	0.24%	100

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vigilare Wealth Management's REGN Position: Q1 2022 in Review

Vigilare Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 470 shares — an estimated $297K sold.

Vigilare Wealth Management first reported a position in REGN in Q3 2020 and held it in 5 quarters. The position peaked at $310K in Q1 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Vigilare Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Vigilare Wealth Management sold 470 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $297K.
Vigilare Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Vigilare Wealth Management's Regeneron Pharmaceuticals position peaked at $310K in Q1 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Vigilare Wealth Management's 13F filing for Q1 2022, filed 6 Apr 2022.